Legal Status
Legal Status
Notice
Draft Guidance for Industry on Conjugated Estrogens, USP-LC-MS Method for Both Qualitative Chemical Characterization and Documentation of Qualitative Pharmaceutical Equivalence; Withdrawal of Guidance
A Notice by the Food and Drug Administration on
Document Details
Information about this document as published in the Federal Register.
- Printed version:
- Publication Date:
- 08/12/2005
- Agencies:
- Food and Drug Administration
- Document Type:
- Notice
- Document Citation:
- 70 FR 47217
- Page:
- 47217 (1 page)
- Agency/Docket Number:
- Docket No. 2000D-0835
- Document Number:
- 05-16019
Document Details
-
Enhanced Content - Table of Contents
This tables of contents is a navigational tool, processed from the headings within the legal text of Federal Register documents. This repetition of headings to form internal navigation links has no substantive legal effect.
Enhanced Content - Table of Contents
-
Enhanced Content - Submit Public Comment
- This feature is not available for this document.
Enhanced Content - Submit Public Comment
-
Enhanced Content - Read Public Comments
- This feature is not available for this document.
Enhanced Content - Read Public Comments
-
Enhanced Content - Sharing
- Shorter Document URL
- https://www.federalregister.gov/d/05-16019 https://www.federalregister.gov/d/05-16019
Enhanced Content - Sharing
-
Enhanced Content - Document Tools
These tools are designed to help you understand the official document better and aid in comparing the online edition to the print edition.
-
These markup elements allow the user to see how the document follows the Document Drafting Handbook that agencies use to create their documents. These can be useful for better understanding how a document is structured but are not part of the published document itself.
Display Non-Printed Markup Elements
Enhanced Content - Document Tools
-
-
Enhanced Content - Developer Tools
This document is available in the following developer friendly formats:
- JSON: Normalized attributes and metadata
- XML: Original full text XML
- MODS: Government Publishing Office metadata
More information and documentation can be found in our developer tools pages.
Enhanced Content - Developer Tools
Published Document
This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice; withdrawal.
SUMMARY:
The Food and Drug Administration (FDA) is announcing the withdrawal of a draft guidance for industry entitled “Conjugated Estrogens, USP-LC-MS Method for Both Qualitative Chemical Characterization and Documentation of Qualitative Pharmaceutical Equivalence.” FDA is withdrawing the draft guidance because the published methodology limits the submission of scientifically valid information to the agency that may be based on different methodologies. FDA does not want to dictate the scientific approach for developing adequate methods.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
David J. Cummings, Center for Drug Evaluation and Research (HFD-357), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5187.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
FDA is announcing the withdrawal of a draft guidance for industry entitled “Conjugated Estrogens, USP-LC-MS Method for Both Qualitative Chemical Characterization and Documentation of Qualitative Pharmaceutical Equivalence.” The agency announced the availability of the guidance in the Federal Register of March 9, 2000 (65 FR 12556). The draft guidance was originally intended to provide recommendations to applicants on how to use the liquid chromatography mass spectrometry (LC-MS) method to address both qualitative chemical characterization and qualitative pharmaceutical equivalence for natural source conjugated estrogens. FDA is withdrawing the guidance because advances in technology allow for the possibility of using different methodologies. FDA does not want to inhibit companies from using a methodology that might provide additional scientific data to support characterization and pharmaceutical equivalence for conjugated estrogens in the future. If submitted, these data would be evaluated to determine applicability of the method before an application could be approved.
Start SignatureDated: August 5, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05-16019 Filed 8-11-05; 8:45 am]
BILLING CODE 4160-01-S